Stock ATHE ALTERITY THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-07-05 EDT 		5-day change 1st Jan Change
1.827 USD +0.68% Intraday chart for Alterity Therapeutics Limited +0.96% -26.61%
05-08 Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review CI
05-08 Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases
Top Midday Gainers
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
Alterity Dispatches Documents Of Planned Share Sale
Alterity Therapeutics Concludes Second Tranche of Placement of AU$3.5 Million; Shares Plunge 20%
Alterity Therapeutics to Raise Up to AU$2 Million Via Share Purchase Plan
Top Premarket Decliners
Sector Update: Health Care Stocks Rise Late Afternoon
Sector Update: Health Care
Top Midday Gainers
Alterity Therapeutics Shares Surge Pre-Bell as Potential Parkinson's Disease Treatment Yields 'Promising New Data' in Monkeys
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
Top Premarket Decliners
Alterity Therapeutics Raises AU$4.8 Million Via Share Placement
Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATH Stock
  4. ATHE Stock
  5. News Alterity Therapeutics Limited
  6. Other languages